Showing results (31-40 of 59) with videos related to
Sort By:
Pageof 6
Antiviral Research|March 6, 2020
Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primatesVincent Madelain, Aurélie Duthey, France Mentré, et al.The Lancet. Infectious Diseases|January 18, 2017
Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort studyJean-François Etard, Mamadou Saliou Sow, Sandrine Leroy, et al.Nature Communications|July 26, 2020
Long-lasting severe immune dysfunction in Ebola virus disease survivorsAurélie Wiedemann, Emile Foucat, Hakim Hocini, et al.Vaccines|June 24, 2022
Natural History of Sudan ebolavirus to Support Medical Countermeasure DevelopmentCaroline Carbonnelle, Marie Moroso, Delphine Pannetier, et al.Plos One|June 10, 2016
Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea PigsOlivier Reynard, Frédéric Jacquot, Gwénaëlle Evanno, et al.Plos Neglected Tropical Diseases|February 24, 2017
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targetedThi Huyen Tram Nguyen, Jérémie Guedj, Xavier Anglaret, et al.Science Translational Medicine|June 10, 2021
A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strainsMathieu Mateo, Stéphanie Reynard, Alexandra Journeaux, et al.Virulence|April 19, 2022
Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeysMathieu Mateo, Jimmy Hortion, Emeline Perthame, et al.Science Translational Medicine|October 4, 2019
Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shotMathieu Mateo, Stéphanie Reynard, Xavier Carnec, et al.Blood|September 12, 2023
Hemostasis defects underlying the hemorrhagic syndrome caused by mammarenaviruses in a cynomolgus macaque modelBlaise Lafoux, Nicolas Baillet, Caroline Picard, et al.Pageof 6